세계의 사르탄 시장 보고서(2025년)
Sartans Global Market Report 2025
상품코드 : 1760707
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,516,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,419,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,322,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

사르탄 시장 규모는 향후 몇 년 동안 꾸준한 성장을 보일 것으로 예상됩니다. 이러한 성장 전망은 복합 요법에 대한 관심 증가, 제약 연구 개발에 대한 투자 증가, 신흥 시장의 수요 증가, 의료 인프라의 확대, 생활 습관병의 유행 등 여러 요인에 기인할 수 있습니다. 이 기간 동안 예상되는 주요 동향으로는 의약품 전달 기술의 발전, API를 위한 첨단 제조 공정의 개발, 고정 용량 복합 의약품의 개발, 개인 맞춤형 고혈압 치료의 혁신, 새로운 사르탄 유도체의 개발 등이 있습니다.

고혈압의 유병률이 증가하면서 사르탄 시장의 성장이 촉진될 것으로 예상됩니다. 고혈압은 지속적으로 높은 혈압이 지속되는 질환으로, 심장병, 뇌졸중 및 기타 심각한 건강 합병증의 위험을 높입니다. 고혈압의 발생률은 소금과 가공식품이 많은 식습관과 밀접하게 연관되어 있으며, 이는 체액 저류와 심장에 추가적인 부담을 초래할 수 있습니다. 사르탄은 혈관을 수축시키는 호르몬인 안지오텐신 II를 차단하여 고혈압을 관리합니다. 혈관을 이완시키고 확장시켜 혈압을 낮추고 심장의 부담을 줄이는 것이 사르탄의 주요 작용 메커니즘입니다. 예를들어, 2024년 1월, 미국 심장 협회는 2022년에 고혈압으로 인한 사망자 수가 13만 1,454명으로 2021년 12만 4,508명에서 증가한 것으로 보고했습니다.

사르탄 시장의 선도 기업들은 치료 효능과 환자의 순응도를 개선하기 위해 정제 형태의 사르탄과 같은 첨단 제품 개발에 주력하고 있습니다. 이러한 경구용 약물은 사르탄 의약품을 함유하고 있으며, 안지오텐신 II의 효과를 차단하여 혈관을 이완시키고 혈압을 낮춥니다. 예를 들어, 2024년 7월, 인도에 본사를 둔 제약 회사인 Zydus Lifesciences는 Diovan이라는 브랜드명으로 판매되는 Valsartan Tablets USP (40mg, 80mg)에 대해 미국 식품의약국(FDA)의 승인을 받았습니다. 이 정제는 고혈압, 심부전 치료 및 성인 심장 마비 후 생존율 개선을 위해 처방되며, 1세 이상의 소아 환자에게도 적합합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Sartans, also known as angiotensin II receptor blockers (ARBs), are medications commonly prescribed to manage high blood pressure (hypertension) and heart failure. They work by blocking the action of angiotensin II, a hormone that constricts blood vessels, thereby promoting vessel relaxation, lowering blood pressure, and improving circulation. Sartans help reduce the risk of strokes, kidney damage, and heart attacks in individuals with specific cardiovascular conditions.

The main types of sartans include valsartan, telmisartan, losartan, irbesartan, azilsartan, and olmesartan. Valsartan, an angiotensin II receptor blocker (ARB), lowers blood pressure and reduces heart strain by relaxing blood vessels. It is distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Valsartan is used for several applications, including hypertension, cardiovascular diseases, kidney diseases, and more, and is employed by various end-users such as hospitals, diagnostic laboratories, and others.

The sartans market research report is one of a series of new reports from The Business Research Company that provides sartans market statistics, including the sartans industry global market size, regional shares, competitors with the sartans market share, detailed sartans market segments, market trends, and opportunities, and any further data you may need to thrive in the sartans industry. This sartans market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sartans market size has grown steadily in recent years. It will grow from $21.36 billion in 2024 to $22.39 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth during the historic period can be attributed to factors such as the growing adoption of sedentary lifestyles, the increasing incidence of obesity, rising awareness about cardiovascular diseases, higher healthcare expenditure, and the rising demand for generic antihypertensive drugs.

The sartans market size is expected to see steady growth in the next few years. It will grow to $26.66 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The forecasted growth can be attributed to several factors, including a heightened focus on combination therapies, increased investments in pharmaceutical R&D, rising demand in emerging markets, expanded healthcare infrastructure, and the growing prevalence of lifestyle-related disorders. Key trends expected during this period include advancements in drug delivery technologies, the development of advanced manufacturing processes for APIs, the creation of fixed-dose combination drugs, innovations in personalized hypertension treatments, and the development of novel sartan derivatives.

The rising prevalence of hypertension is expected to drive the growth of the sartans market. Hypertension, a condition characterized by persistently high blood pressure, increases the risk of heart disease, stroke, and other serious health complications. The growing incidence of hypertension is largely linked to diets high in salt and processed foods, which can lead to fluid retention and added strain on the heart. Sartans help manage hypertension by blocking angiotensin II, a hormone that causes blood vessels to constrict. By relaxing and widening the blood vessels, sartans lower blood pressure and reduce the heart's workload. For example, in January 2024, the American Heart Association reported that high blood pressure was responsible for 131,454 deaths in 2022, an increase from 124,508 deaths in 2021. As a result, the rising prevalence of hypertension is driving the growth of the sartans market.

Leading companies in the sartans market are focusing on developing advanced products, such as tablet-form sartans, to improve treatment efficacy and patient adherence. These oral medications contain sartan drugs, which block the effects of angiotensin II, promoting blood vessel relaxation and lowering blood pressure. For example, in July 2024, Zydus Lifesciences, an India-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Valsartan Tablets USP (40 mg, 80 mg), marketed under the brand name Diovan. These tablets are prescribed to treat hypertension, heart failure, and to improve survival after a heart attack in adults, and are also suitable for pediatric patients aged one year and older.

In April 2025, Scienture Holdings, Inc., a U.S.-based manufacturer of sartans, partnered with Saptalis Pharmaceuticals to develop and distribute Arbli (losartan potassium oral suspension, 10 mg/mL). This collaboration includes warehousing and distribution agreements with strategic partners to ensure market readiness for the first FDA-approved ready-to-use oral liquid losartan, addressing unmet needs in the treatment of hypertension. Saptalis Pharmaceuticals is a U.S.-based pharmaceutical company.

Major players in the sartans market are Viatris Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Vasudha Pharma Chem Ltd., Unichem Laboratories Ltd., Global Pharma Tek, Manus Aktteva Biopharma LLP, Emcure Pharmaceuticals Ltd., Wellona Pharma, JPM Pharma & Chemicals Pvt. Ltd.

North America was the largest region in the sartans market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sartans report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sartans market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sartans market consists of sales of candesartan, eprosartan, and fimasartan. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sartans Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sartans market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for sartans ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sartans market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Sartans Market Characteristics

3. Sartans Market Trends And Strategies

4. Sartans Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Sartans Growth Analysis And Strategic Analysis Framework

6. Sartans Market Segmentation

7. Sartans Market Regional And Country Analysis

8. Asia-Pacific Sartans Market

9. China Sartans Market

10. India Sartans Market

11. Japan Sartans Market

12. Australia Sartans Market

13. Indonesia Sartans Market

14. South Korea Sartans Market

15. Western Europe Sartans Market

16. UK Sartans Market

17. Germany Sartans Market

18. France Sartans Market

19. Italy Sartans Market

20. Spain Sartans Market

21. Eastern Europe Sartans Market

22. Russia Sartans Market

23. North America Sartans Market

24. USA Sartans Market

25. Canada Sartans Market

26. South America Sartans Market

27. Brazil Sartans Market

28. Middle East Sartans Market

29. Africa Sartans Market

30. Sartans Market Competitive Landscape And Company Profiles

31. Sartans Market Other Major And Innovative Companies

32. Global Sartans Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sartans Market

34. Recent Developments In The Sartans Market

35. Sartans Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기